Congratulations to Lutz and Malena on their new publication in Nature Immunology
picture taken by MedizinFoto Köln
The study characterizes 007, a broadly neutralizing HIV-1 antibody with strong activity across multiple viral strains. Unlike classical V3 glycan antibodies, 007 binds independently of the N332 glycan, making it resistant to common escape mutations. Structural analyses revealed a distinct binding mode, and experiments in humanized mice demonstrated antiviral activity in vivo, highlighting its potential for HIV-1 prevention, therapy, and vaccine development.
Our results have now been published in Nature Immunology.